146 related articles for article (PubMed ID: 35881702)
1. Myth and Truth in Opioid Consumption with Intrathecal Morphine Pump Implantation in Chronic Pain: A Retrospective Cohort Study with Claims Database in South Korea.
Yoo Y; Oh JH; Lee H; Choi H; Joo S; Han AH; Moon JY
Pain Med; 2023 Jan; 24(1):79-88. PubMed ID: 35881702
[TBL] [Abstract][Full Text] [Related]
2. Implantable drug delivery systems (IDDS) after failure of comprehensive medical management (CMM) can palliate symptoms in the most refractory cancer pain patients.
Smith TJ; Coyne PJ
J Palliat Med; 2005 Aug; 8(4):736-42. PubMed ID: 16128647
[TBL] [Abstract][Full Text] [Related]
3. An implantable drug delivery system (IDDS) for refractory cancer pain provides sustained pain control, less drug-related toxicity, and possibly better survival compared with comprehensive medical management (CMM).
Smith TJ; Coyne PJ; Staats PS; Deer T; Stearns LJ; Rauck RL; Boortz-Marx RL; Buchser E; Català E; Bryce DA; Cousins M; Pool GE
Ann Oncol; 2005 May; 16(5):825-33. PubMed ID: 15817596
[TBL] [Abstract][Full Text] [Related]
4. Intrathecal Drug Delivery Systems for Refractory Pancreatic Cancer Pain: Observational Follow-up Study Over an 11-Year Period in a Comprehensive Cancer Center.
Carvajal G; Dupoiron D; Seegers V; Lebrec N; Boré F; Dubois PY; Leblanc D; Delorme T; Jubier-Hamon S
Anesth Analg; 2018 Jun; 126(6):2038-2046. PubMed ID: 29543644
[TBL] [Abstract][Full Text] [Related]
5. Long-term intrathecal drug administration for chronic nonmalignant pain.
Duarte RV; Raphael JH; Sparkes E; Southall JL; LeMarchand K; Ashford RL
J Neurosurg Anesthesiol; 2012 Jan; 24(1):63-70. PubMed ID: 21904220
[TBL] [Abstract][Full Text] [Related]
6. Perioperative Opioid Consumption and Clinical Outcomes in Surgical Patients With a Pre-existing Opioid-Based Intrathecal Drug Delivery System.
D'Souza RS; Warner MA; Olatoye OO; Langford BJ; Bruns DL; Schroeder DR; Mauck WD; Schaefer KK; Warner NS
Anesth Analg; 2022 Jan; 134(1):35-43. PubMed ID: 34260427
[TBL] [Abstract][Full Text] [Related]
7. Age-dependent intrathecal opioid escalation in chronic noncancer pain patients.
Hayek SM; Veizi IE; Narouze SN; Mekhail N
Pain Med; 2011 Aug; 12(8):1179-89. PubMed ID: 21810164
[TBL] [Abstract][Full Text] [Related]
8. Randomized clinical trial of an implantable drug delivery system compared with comprehensive medical management for refractory cancer pain: impact on pain, drug-related toxicity, and survival.
Smith TJ; Staats PS; Deer T; Stearns LJ; Rauck RL; Boortz-Marx RL; Buchser E; Català E; Bryce DA; Coyne PJ; Pool GE;
J Clin Oncol; 2002 Oct; 20(19):4040-9. PubMed ID: 12351602
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of intrathecal drug delivery system for refractory cancer pain patients: a single tertiary medical center experience.
Lin CP; Lin WY; Lin FS; Lee YS; Jeng CS; Sun WZ
J Formos Med Assoc; 2012 May; 111(5):253-7. PubMed ID: 22656395
[TBL] [Abstract][Full Text] [Related]
10. Clinical experience with intrathecal bupivacaine in combination with opioid for the treatment of chronic pain related to failed back surgery syndrome and metastatic cancer pain of the spine.
Deer TR; Caraway DL; Kim CK; Dempsey CD; Stewart CD; McNeil KF
Spine J; 2002; 2(4):274-8. PubMed ID: 14589479
[TBL] [Abstract][Full Text] [Related]
11. Successful Discontinuation of Systemic Opioids After Implantation of an Intrathecal Drug Delivery System.
Caraway D; Walker V; Becker L; Hinnenthal J
Neuromodulation; 2015 Aug; 18(6):508-15; discussion 515-6. PubMed ID: 26053626
[TBL] [Abstract][Full Text] [Related]
12. Systemic Opioid Reduction and Discontinuation Following Implantation of Intrathecal Drug-Delivery Systems for Chronic Pain: A Retrospective Cohort Analysis.
Hatheway JA; Bansal M; Nichols-Ricker CI
Neuromodulation; 2020 Oct; 23(7):961-969. PubMed ID: 31603605
[TBL] [Abstract][Full Text] [Related]
13. Long-term Outcomes Using Intrathecal Drug Delivery Systems in Complex Regional Pain Syndrome.
Herring EZ; Frizon LA; Hogue O; Mejia JU; Rosenquist R; Bolash RB; Machado AG; Nagel SJ
Pain Med; 2019 Mar; 20(3):515-520. PubMed ID: 29889241
[TBL] [Abstract][Full Text] [Related]
14. Patient selection and outcomes using a low-dose intrathecal opioid trialing method for chronic nonmalignant pain.
Grider JS; Harned ME; Etscheidt MA
Pain Physician; 2011; 14(4):343-51. PubMed ID: 21785477
[TBL] [Abstract][Full Text] [Related]
15. Intrathecal Morphine Infusion Therapy in Management of Chronic Pain: Present and Future Implementation in Korea.
Kim EJ; Moon JY; Kim YC; Park KS; Yoo YJ
Yonsei Med J; 2016 Mar; 57(2):475-81. PubMed ID: 26847303
[TBL] [Abstract][Full Text] [Related]
16. Combination of intrathecal opioids with bupivacaine attenuates opioid dose escalation in chronic noncancer pain patients.
Veizi IE; Hayek SM; Narouze S; Pope JE; Mekhail N
Pain Med; 2011 Oct; 12(10):1481-9. PubMed ID: 21943351
[TBL] [Abstract][Full Text] [Related]
17. Prospective study of 3-year follow-up of low-dose intrathecal opioids in the management of chronic nonmalignant pain.
Hamza M; Doleys D; Wells M; Weisbein J; Hoff J; Martin M; Soteropoulos C; Barreto J; Deschner S; Ketchum J
Pain Med; 2012 Oct; 13(10):1304-13. PubMed ID: 22845187
[TBL] [Abstract][Full Text] [Related]
18. Intrathecal Opioid Therapy for Non-Malignant Chronic Pain: A Long-Term Perspective.
Kleinmann B; Wolter T
Neuromodulation; 2017 Oct; 20(7):719-726. PubMed ID: 28560830
[TBL] [Abstract][Full Text] [Related]
19. Initiation of Intrathecal Drug Delivery Dramatically Reduces Systemic Opioid Use in Patients With Advanced Cancer.
Sindt JE; Odell DW; Dalley AP; Brogan SE
Neuromodulation; 2020 Oct; 23(7):978-983. PubMed ID: 32459393
[TBL] [Abstract][Full Text] [Related]
20. Intrathecal drug delivery for chronic pain management-scope, limitations and future.
Czernicki M; Sinovich G; Mihaylov I; Nejad B; Kunnumpurath S; Kodumudi G; Vadivelu N
J Clin Monit Comput; 2015 Apr; 29(2):241-9. PubMed ID: 25173564
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
